Eliminate the Pain Wisdom Teeth Cause
We invented a minimally invasive dental treatment for kids that prevents wisdom teeth from ever forming. Our one-minute treatment is designed to eliminate the need for painful wisdom teeth removal. Dentists who provide this preventive care will no longer need to refer their patients to oral surgeons for painful wisdom teeth surgeries. TriAgenics’ goal is to make our revolutionary treatment the new standard of care.
Buy stock in the company that intends to disrupt the $5B wisdom tooth extraction market¹.
Investment Highlights
Patented Technology
37 issued patents
Proven Medtech Management Team
Align Technology and IBM
FDA
Currently seeking FDA medical device clearance
10M Wisdom Teeth Are Extracted Every Year in the United States Alone
Wisdom teeth removal is the most common surgery performed in the U.S. As a result, 5 million people² experience painful swelling, dry sockets, missed school, missed work, and recoveries that can take weeks. This procedure also involves serious risks, such as nerve damage, infections, and complications from anesthesia. U.S. consumers spend more than $5 billion yearly for extractions and related care. We’ve come to accept this as unavoidable – until now.
$5 Billion
Designed to Be a Safer, Faster, Pain-Free Alternative
Before wisdom teeth form, they exist beneath the gums as small tooth buds. Our breakthrough Zero3 TBA (tooth bud ablation) procedure is designed to gently eliminate these tooth buds in children ages 6-12. It takes about a minute per tooth bud, requires no cutting or stitches, and kids can immediately eat, play, or return to school without experiencing the pain normally associated with traditional wisdom teeth removal.
Target Age Range
The Ultimate Win-Win For Dentists, Patients and TriAgenics
Rather than having wisdom teeth removed by oral surgeons, family dentists will have a quick preventive-care procedure that prevents wisdom teeth from ever forming. General dentists can potentially increase their annual revenues by $300,000 by treating 10 patients per month. TriAgenics plans to sell its Zero3 surgical kits to dentists for $350 per tooth bud at 75% margins. Similar to the way Invisalign clear braces changed the way people get their teeth straightened, we believe Zero3 TBA will be the way people treat wisdom teeth.
.avif)
.avif)
.avif)
.avif)
From FDA Clearance to Global Expansion
Following FDA clearance, there are millions of kids that can benefit from Zero3 TBA every year. Here’s how we plan to bring Zero3 TBA to the dental market.
FDA Clearance.
We are committed to meet all U.S. Food and Drug Administration regulations and guidelines.
Clinical Trials.
We plan to conduct human clinical trials to demonstrate safety and effectiveness.
Commercial Launch.
Post FDA clearance, we first plan to commercially launch to general dentists in the U.S.
Global Expansion
We have secured international patents in Canada, Mexico, Australia, and Europe..
New standard of care.
Just as clear aligners are replacing metal braces, Zero3 TBA is designed to replace outdated wisdom tooth extractions with a fast, non-invasive alternative.
Practice-level economics.
Align turned orthodontists and general dentists into active promoters by giving them a recurring revenue stream. Zero3 TBA gives general dentists that same opportunity, keeping wisdom tooth procedures in-house.
Scalable, guided system.
Align Technology’s success relied on clear aligners custom-fit to each patient. TriAgenics uses the same principle: a patient-specific, 3D-printed guide that ensures safe, precise targeting in every case.
Broad IP.
TriAgenics holds a broad patent portfolio — 37 issued U.S. and international patents..
Exclusive Investor Perks
Tested Founders, Engineers, and Dental Leaders
From pioneering medical devices to scaling category-defining dental technologies, this team brings the exact experience needed to make Zero3 TBA the next go-to standard of care.
• Founder, CEO and sole shareholder of Oregon Dental Care, a large individual group dental practice in Oregon
• Principal founder of Laserdyne
Corporation. Laserdyne remains the #1 selling general-purpose laser machining system worldwide
• 10 years experience as VP of business development with a MedTech company
• Over 25 years of manufacturing and engineering leadership experience in the medical device industry
• 15 years with IBM in automation engineering
• VP of Global Marketing at Align Technology during initial commercial ramp
• Over 30 years medical device commercial experience including CEO of InSound Medical and other medical device start-ups
Frequently Asked Questions
Why invest in startups?
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
How much can I invest?
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
How do I calculate my net worth?
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Who can invest in a Regulation CF Offering?
Individuals over 18 years of age can invest.
What do I need to know about early-stage investing? Are these investments risky?
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You will not have voting rights because you are buying non-voting common stock. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
When will I get my investment back?
The Common Stock (the "Shares") of TriAgenics Inc (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Can I sell my shares?
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.
There is no guarantee your shares will be marketable.
Exceptions to limitations on selling shares during the one-year lockup period:
In the event of death, divorce, or similar circumstance, shares can be transferred to:
• The company that issued the securities;
• An accredited investor;
• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships).
What happens if a company does not reach their funding target?
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
How can I learn more about a company's offering?
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
What if I change my mind about investing?
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com
How do I keep up with how the company is doing?
At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
What relationship does the company have with DealMaker Securities?
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.
What kind of shares are you issuing?
Non-voting, common stock.
Where can I find the company’s SEC filings?
All of TriAgenics’ regulatory filings, including financial reports, can be found here:
How much are you raising?
$3,000,000.00
How will I get a return on my investment?
A. Investing in startups is risky and there is no guarantee you will get a return on your investment. However, an exit opens up the opportunity where you could convert your shares into cash or a more liquid asset. Exits include going public, getting acquired by a larger company, or our company buying back shares. If the value of our company grows, then you have a higher potential of making a profit on your investment during one of these exits.
B. You are investing in a pre-revenue company. Success will be measured in progress towards revenue. Future liquidation events could include acquisition or an IPO.
When will I receive my shares?
Shares will be rewarded after the investment funds clear. This typically takes around 3 weeks after investment.
Are there higher fees if you invest via credit card vs. ACH?
No, costs are the same, regardless of how you invest.
How do I know people will buy this solution?
TriAgenics has presented at a number of dental seminars and talked with hundreds of dentists regarding the feasibility of the Zero3 TBA procedure. Dentists have embraced Zero3 TBA because it is a minimally invasive approach to wisdom teeth management. However, there is no assurance that this technology will be adopted by dental professionals or consumers.
Why didn't a bigger company do this already?
During Dr. Colby’s 40 years of dental practice, he grew tired of seeing his patients suffer from the many painful problems wisdom teeth cause. Instead of waiting for an established company to address this problem, he developed TriAgenics’ patented treatment, which is designed to eliminate wisdom teeth issues by preventing these troublesome teeth from ever forming.
How do you plan to use the proceeds from this funding round?
The primary use of funds is to continue to pursue FDA clearance.
What is the current valuation of the Company?
TriAgenics’ pre-money valuation is $55.5 million.
Why should I invest?
This is an opportunity to invest in a product that has the potential to eliminate the most common surgery performed on young adults. If TriAgenics is successful, it may replace the $5 billion wisdom tooth extraction market and provide a better experience for children and their parents.
Will you be paying out dividends to investors?
It is unusual for pre-revenue medical technology companies to pay dividends. Currently, TriAgenics has no plans to pay dividends.
What’s the Company's core business?
TriAgenics is a pre-revenue company that is working to provide a safe, effective and simple way for dental professionals to prevent the broad array of diseases, extensive damage, and lifelong hazards caused by wisdom teeth. The company has developed a minimally invasive dental procedure designed for children ages 6-12 to prevent wisdom teeth from ever forming.
The procedure is called Zero3 TBA (tooth bud ablation). There are no stitches, and the procedure is expected to have no significant recovery time or significant complications, which means no painful infections or dry sockets that can follow wisdom teeth extractions. The best part of third molar ablation is that patients are expected to have dramatically improved lifelong outcomes compared to the traditional practice of allowing these troublesome teeth to form and then removing them later in patients’ lives.
Where are your headquarters located?
Redmond, Oregon, USA.
How many employees does your Company have?
Three employees and a number of consultants retained on a contract basis.
How many patents do you have?
TriAgenics currently has 37 patents that protect its treatment and technology.
What does your path to profitability look like?
Should we receive FDA clearance, our pathway to profitability will initially focus on the introduction of Zero3 TBA to dentists in the U.S. Once TriAgenics has demonstrated high demand among dentists and is cash-flow positive in the U.S., the company may pursue international markets.
Who are your competitors?
The TriAgenics’ product has no direct competitors at this time. Zero3 TBA is the only treatment system designed to eliminate painful complications associated with traditional wisdom teeth removal by preventing these troublesome teeth from ever forming.
Who is the main audience target for your product/service?
TriAgenics will sell its Zero 3TBA product directly to dentists who, in turn, will sell the Zero3 TBA procedure to parents of children who are indicated for the procedure.